Home › Free Stock Grades › PRME
Prime Medicine, Inc. (PRME) Stock Grade
PRME · Healthcare
C
Market Cap
$519.3M
P/E Ratio
—
Revenue Growth (YoY)
+55.3%
Net Margin
-4342.4%
Return on Equity
—
Dividend Yield
None
About Prime Medicine, Inc.'s fundamentals
Prime Medicine is a biotechnology company with a market capitalization of $519.3 million that is experiencing strong revenue growth of 55.3% year-over-year. However, the company is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -4342.4%, and does not pay a dividend. The company's early-stage development profile is reflected in these metrics, which are typical for biotechnology firms in their clinical or pre-commercial phases.